Methods of Treating a MK2-Mediated Disorder

The European Patent Office granted Bristol-Myers Squibb Company a new patent (EP3969456A1) for methods of treating MK2-mediated disorders, published April 15, 2026. The patent covers C07D compounds classified under C07D 495/14 and lists therapeutic compositions under A61K 31/4353 and A61K 31/551. The patent designation extends to 32 European Contracting States including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

Pharmaceutical companies developing MK2 pathway inhibitors or related kinase-targeted therapies should review this patent for potential freedom-to-operate implications. Generic manufacturers targeting the same therapeutic indication may need to consider licensing strategies or design-around approaches. Research institutions and drug development companies active in inflammatory or oncology kinase research should monitor this IP position as part of their landscape monitoring.